Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.67 Million SEK | 40.21% |
| 2022 | -27.88 Million SEK | 5.03% |
| 2021 | -29.35 Million SEK | 47.9% |
| 2020 | -56.34 Million SEK | 8.76% |
| 2019 | -61.75 Million SEK | -59.51% |
| 2018 | -38.71 Million SEK | -16.07% |
| 2017 | -33.35 Million SEK | -54.44% |
| 2016 | -21.59 Million SEK | -359868.82% |
| 2015 | -6000.00 SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -11.62 Million SEK | 30.29% |
| 2024 Q2 | -5.81 Million SEK | 49.97% |
| 2023 Q1 | -21.05 Million SEK | 24.48% |
| 2023 FY | -16.67 Million SEK | 40.21% |
| 2023 Q4 | -16.67 Million SEK | -121.73% |
| 2023 Q3 | -7.51 Million SEK | 45.91% |
| 2023 Q2 | -13.89 Million SEK | 33.99% |
| 2022 Q1 | -69.19 Million SEK | -135.7% |
| 2022 Q2 | -46.92 Million SEK | 32.19% |
| 2022 Q3 | -39.36 Million SEK | 16.1% |
| 2022 Q4 | -27.88 Million SEK | 29.18% |
| 2022 FY | -27.88 Million SEK | 5.03% |
| 2021 FY | -29.35 Million SEK | 47.9% |
| 2021 Q1 | -47.26 Million SEK | 16.11% |
| 2021 Q3 | -42.96 Million SEK | 20.52% |
| 2021 Q2 | -54.05 Million SEK | -14.36% |
| 2021 Q4 | -29.35 Million SEK | 31.67% |
| 2020 Q2 | -40.63 Million SEK | 21.61% |
| 2020 Q1 | -51.83 Million SEK | 16.07% |
| 2020 Q4 | -56.34 Million SEK | -26.37% |
| 2020 FY | -56.34 Million SEK | 8.76% |
| 2020 Q3 | -44.58 Million SEK | -9.74% |
| 2019 FY | -61.75 Million SEK | -59.51% |
| 2019 Q4 | -61.75 Million SEK | -401.79% |
| 2019 Q3 | -12.3 Million SEK | 48.45% |
| 2019 Q2 | -23.87 Million SEK | 20.56% |
| 2019 Q1 | -30.04 Million SEK | 22.39% |
| 2018 Q2 | -17.81 Million SEK | 34.56% |
| 2018 Q1 | -27.22 Million SEK | 18.38% |
| 2018 FY | -38.71 Million SEK | -16.07% |
| 2018 Q4 | -38.71 Million SEK | -269.5% |
| 2018 Q3 | -10.47 Million SEK | 41.19% |
| 2017 FY | -33.35 Million SEK | -54.44% |
| 2017 Q1 | -31.27 Million SEK | -44.8% |
| 2017 Q2 | -28.11 Million SEK | 10.11% |
| 2017 Q3 | -25.66 Million SEK | 8.72% |
| 2017 Q4 | -33.35 Million SEK | -29.99% |
| 2016 Q2 | -24.63 Million SEK | 0.0% |
| 2016 FY | -21.59 Million SEK | -359868.82% |
| 2016 Q3 | -23.46 Million SEK | 4.74% |
| 2016 Q4 | -21.59 Million SEK | 7.97% |
| 2015 FY | -6000.00 SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | 49.789% |
| Biovica International AB (publ) | -58.73 Million SEK | 71.619% |
| Cantargia AB (publ) | -139.74 Million SEK | 88.071% |
| CombiGene AB (publ) | -101.44 Million SEK | 83.567% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -460.902% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 43.266% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 70.171% |
| Fluicell AB (publ) | -2.76 Million SEK | -503.33% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 94.934% |
| Mendus AB (publ) | -96.29 Million SEK | 82.688% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 87.933% |
| I-Tech AB | -83.26 Million SEK | 79.979% |
| Intervacc AB (publ) | -88.16 Million SEK | 81.091% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 47.787% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 131.321% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 12.539% |
| OncoZenge AB (publ) | -12.62 Million SEK | -32.019% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 66.616% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 110.038% |
| Lipum AB (publ) | -8.46 Million SEK | -96.929% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 66.674% |
| Ziccum AB (publ) | -2.13 Million SEK | -680.066% |
| BioArctic AB (publ) | -606.58 Million SEK | 97.252% |
| Genovis AB (publ.) | -43.94 Million SEK | 62.063% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.57% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 80.094% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 57.671% |
| Aptahem AB (publ) | 2.9 Million SEK | 673.12% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 95.003% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 87.127% |
| Kancera AB (publ) | -45.69 Million SEK | 63.517% |
| Saniona AB (publ) | 40.44 Million SEK | 141.214% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 63.133% |
| AcouSort AB (publ) | -23.98 Million SEK | 30.501% |
| Xintela AB (publ) | -7.8 Million SEK | -113.472% |
| Abliva AB (publ) | -57.24 Million SEK | 70.877% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 79.721% |
| Amniotics AB (publ) | -5.63 Million SEK | -195.987% |
| 2cureX AB (publ) | -13.4 Million SEK | -24.375% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -671.402% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 408.704% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 112.375% |
| Biosergen AB | -1.88 Million SEK | -785.289% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 181.277% |
| Corline Biomedical AB | -17.01 Million SEK | 2.01% |
| NextCell Pharma AB | -46.79 Million SEK | 64.373% |
| Nanologica AB (publ) | -9.38 Million SEK | -77.567% |
| LIDDS AB (publ) | -13.51 Million SEK | -23.372% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 91.438% |
| BioInvent International AB (publ) | -236.3 Million SEK | 92.946% |
| SynAct Pharma AB | -61.75 Million SEK | 73.008% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 22.157% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -26.009% |
| Alzinova AB (publ) | -21.22 Million SEK | 21.464% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 19.829% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 75.09% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -221.758% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 80.093% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1706.067% |
| Simris Alg AB (publ) | 85.07 Million SEK | 119.594% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 79.692% |